(Total Views: 411)
Posted On: 05/07/2025 5:47:24 PM
Post# of 154563
What I know dostarlimab is mostly targeting MSI CRC witch make up about 15% of all CRC patients ..
Leronlimab is going mostly after the MSS CRC which makes about 80-85% of patients..
Dostarlimab is a monoclonal antibody that inhibits PD-1 receptor .
They have a very good results on MSI CRC.
MSI is microsatellite instability ..
MSS is microsatellite stability ..
Indicate how stable is DNA in a tumor.
Leronlimab is going mostly after the MSS CRC which makes about 80-85% of patients..
Dostarlimab is a monoclonal antibody that inhibits PD-1 receptor .
They have a very good results on MSI CRC.
MSI is microsatellite instability ..
MSS is microsatellite stability ..
Indicate how stable is DNA in a tumor.
(11)
(0)
